---
title: "Merck KGaA (MKKGY.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/MKKGY.US.md"
symbol: "MKKGY.US"
name: "Merck KGaA"
industry: "Pharmaceuticals"
datetime: "2026-05-21T06:15:42.574Z"
locales:
  - [en](https://longbridge.com/en/quote/MKKGY.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/MKKGY.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/MKKGY.US.md)
---

# Merck KGaA (MKKGY.US)

## Company Overview

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company’s Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.emdgroup.com](https://www.emdgroup.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:18.000Z

**Overall: C (0.42)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 42 / 189 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 6.64% |  |
| Net Profit YoY | -2.54% |  |
| P/B Ratio | 1.83 |  |
| Dividend Ratio | 1.76% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 62325408811.30 |  |
| Revenue | 24478117550.09 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 8.50% | B |
| Profit Margin | 12.08% | B |
| Gross Margin | 59.70% | A |
| Revenue YoY | 6.64% | C |
| Net Profit YoY | -2.54% | C |
| Total Assets YoY | 13.79% | B |
| Net Assets YoY | 5.59% | C |
| Cash Flow Margin | 165.64% | B |
| OCF YoY | 6.64% | C |
| Turnover | 0.41 | C |
| Gearing Ratio | 43.81% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Merck KGaA",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "6.64%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-2.54%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.83",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "1.76%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "62325408811.30",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "24478117550.09",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "8.50%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "12.08%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "59.70%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "6.64%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-2.54%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "13.79%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "5.59%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "165.64%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "6.64%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.41",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "43.81%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 21.07 | 36/189 | 19.35 | 18.58 | 17.79 |
| PB | 1.83 | 82/189 | 1.83 | 1.75 | 1.67 |
| PS (TTM) | 2.55 | 68/189 | 2.61 | 2.46 | 2.36 |
| Dividend Yield | 1.76% | 22/189 | 2.01% | 1.87% | 1.79% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-13T04:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 50% |
| Overweight | 1 | 50% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 28.67 |
| Highest Target | 34.08 |
| Lowest Target | 34.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/MKKGY.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/MKKGY.US/norm.md)
- [Related News](https://longbridge.com/en/quote/MKKGY.US/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**